Funder
Ahvaz Jundishapur University of Medical Sciences
Publisher
Springer Science and Business Media LLC
Reference32 articles.
1. García-Ortiz A, Rodríguez-García Y, Encinas J, Maroto-Martín E, Castellano E, Teixidó J et al (2021) The role of tumor microenvironment in multiple myeloma development and progression. Cancers 13(2):217
2. Podar K, Tai Y-T, Lin BK, Narsimhan RP, Sattler M, Kijima T et al (2002) Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with β1 integrin- and phosphatidylinositol 3-kinase-dependent PKCα Activation*. J Biol Chem 277(10):7875–7881
3. Hussain A, Almenfi HF, Almehdewi AM, Hamza MS, Bhat MS, Vijayashankar NP (2019) Laboratory features of newly diagnosed multiple myeloma patients. Cureus. 11(5):e4716
4. Allmeroth K, Horn M, Kroef V, Miethe S, Müller R-U, Denzel MS (2021) Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myeloma. Leukemia 35(3):887–892
5. Podar K, Gouill SL, Zhang J, Opferman JT, Zorn E, Tai YT et al (2008) A pivotal role for Mcl-1 in Bortezomib-induced apoptosis. Oncogene 27(6):721–731